Pre-made Bevacizumab benchmark antibody ( Whole mAb, anti-VEGFA therapeutic antibody, Anti-VPF/VEGF/MVCD1 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Bevacizumab biosimilar, Whole mAb, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Bevacizumab, sold under the brand name Avastin, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal).
| Products Name (INN Index) | Pre-Made Bevacizumab biosimilar, Whole mAb, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibody |
|---|---|
| INN Name | Bevacizumab |
| Target | VEGFA |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | 1bj1:HL:KJ |
| 99% SI Structure | None |
| 95-98% SI Structure | 6bft:AB:HL/1cz8:HL:YX |
| Year Proposed | 2000 |
| Year Recommended | 2001 |
| Conditions Approved | Breast cancer,Cervical cancer,Colorectal cancer,Glioblastoma,Glioma,Non-small cell lung cancer,Ovarian cancer,Renal cell carcinoma,Fallopian tube cancer,Peritoneal cancer |
| Conditions Active | Head and neck cancer,Biliary cancer,Brain metastases,Endometrial cancer,Ewing's sarcoma,Gynaecological cancer,Hodgkin's disease,Intestinal cancer,Liver cancer,Liver metastases,Malignant melanoma,Meni |
| Conditions Discontinued | Carcinoid tumour,Chronic lymphocytic leukaemia,Diffuse large B cell lymphoma,Eye disorders,Gastric cancer,Gastrointestinal stromal tumours,Mesothelioma,Oesophageal cancer,Pancreatic cancer,Prostate c |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | VEGFA |
| Package |
